Generic Dexone depresses formation, release, and activity of endogenous mediators of inflammation, including prostaglandins, kinins, histamine, liposomal enzymes, and complement expression. Also modifies the body's immune response.
Clinical Oncology NewsLen-Dex Induction Delays Progression in Smoldering MyelomaClinical Oncology NewsSan Diego—Patients with high-risk asymptomatic multiple myeloma, characterized as smoldering multiple myeloma (SMM), can delay their time to progression with an induction regimen of lenalidomide and dexamethasone (Len-Dex), according to the results of .
Chemo combination promising for multiple myeloma - Medical Xpress
Chemo combination promising for multiple myelomaMedical XpressFor patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according to a study published online April 30 in .